Codex DNA, Inc. (DNAY) News
Filter DNAY News Items
DNAY News Results
|Loading, please wait...|
DNAY News Highlights
- For DNAY, its 30 day story count is now at 7.
- Over the past 17 days, the trend for DNAY's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DNA, DECK and LINK are the most mentioned tickers in articles about DNAY.
Latest DNAY News From Around the Web
Below are the latest news stories about Codex DNA Inc that investors may wish to consider to help them evaluate DNAY as an investment opportunity.
SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company’s chief executive officer, will present virtually at the 42nd Annual Cowen Healthcare Conference on Wednesday, March 9th at 2:10 pm Eastern time / 11:10 am Pacific Time. Additionally, Todd will participate in a ‘Synthetic Biology Enabling Technologies Panel’ on Monday, March 7th at 10:30 am Eastern time / 7:3
The following slide deck was published by Codex DNA, Inc. in conjunction with this event....
SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that members of its management team will be participating in the SVB Leerink 11 th Annual Global Healthcare Conference. An updated version of Codex DNA’s corporate presentation will be available on Wednesday, February 16 th at 12:00 pm Eastern time / 9:00 am Pacific time.
Despite double-digit gains today, Codex DNA (DNAY +22.7%) is still down ~38% from its IPO in June 2021. Its IPO was priced at $16. In afternoon trading today, shares stood at $9.33 Since the IPO, trading in Codex DNA has been volatile. Last month, Codex benefitted from a deal with...
Codex DNA Showcases Potential of Groundbreaking SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Vaccines and Therapeutics
Proprietary short oligo ligation assembly (SOLA) technology used to enzymatically synthesize DNA fragments for the construction of full-length H1 and N1 genes from influenza A virusInitial performance results show potentially significant quality, time, and cost advantages compared to traditional chemical synthesis and alternative enzymatic DNA synthesis approaches SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology system
No summary available.
Pfizer Inc (NYSE: PFE) has signed on two partners in an effort to become an mRNA powerhouse. Pfizer will offer milestone payments of over 0 million to Codex DNA Inc (NASDAQ: DNAY) for access to the biotech's novel enzymatic DNA synthesis technology in the first deal. The agreement will similarly be used to develop new mRNA vaccines and therapeutics. The financial terms, which were not spelled out, include an upfront payment and the milestones, which Codex said: "could be earned in the near term.
Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and Development of mRNA-based Vaccines and Biotherapies
Pfizer and Codex DNA agree to strategic, multiyear, early access research collaboration, leveraging Codex DNA’s novel enzymatic DNA synthesis (EDS) technologyPfizer’s successful development and commercialization of licensed products could result in milestone payments in excess of $100 million SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a leader in the development of automated solutions for on-demand synthesis of genes and mRNA, today announced a strategic collabo
By Sam Boughedda
Wednesday will go down in history for Codex DNA (NASDAQ: DNAY). The genetics-focused biotech saw its share price rocket 39% higher, thanks to a potentially very lucrative deal with a deep-pocketed pharmaceutical giant. Codex DNA disclosed in a regulatory filing that it has entered into a research collaboration and license agreement with U.S. pharmaceutical company Pfizer (NYSE: PFE), these days best known as the co-developer of the Comirnaty coronavirus vaccine.